LCM
NMRA icon

Laurion Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Laurion Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,557
Closed -$304K – 565
2023
Q3 		$304K Buy
+21,557
New +$269K ﹤0.01% 408

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Laurion Capital Management's NMRA Position: Q4 2023 in Review

Laurion Capital Management sold out of Neumora Therapeutics (NMRA) in Q4 2023, closing a stake of 21,557 shares — an estimated $304K sold.

Laurion Capital Management first reported a position in NMRA in Q3 2023 and held it in 1 quarter. The position peaked at $304K in Q3 2023. 60 funds tracked by Wall St. Rank hold NMRA as of Q4 2023.

  • Laurion Capital Management reported no remaining Neumora Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Laurion Capital Management sold 21,557 Neumora Therapeutics shares in Q4 2023, an estimated $304K.
  • Laurion Capital Management first reported a position in Neumora Therapeutics in Q3 2023 and held it in 1 quarter.
  • Laurion Capital Management's Neumora Therapeutics position peaked at $304K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.